{"id":742129,"date":"2011-04-15T06:00:00","date_gmt":"2011-04-15T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/"},"modified":"2026-08-10T13:01:18","modified_gmt":"2026-08-10T17:01:18","slug":"merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/","title":{"rendered":"Merck and Johnson &amp; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae"},"content":{"rendered":"<p class=\"bwalignc\">       Companies settle arbitration proceeding     <\/p>\n<p>WHITEHOUSE STATION, N.J. &amp; NEW BRUNSWICK, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,        and Johnson &amp; Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho        Biotech Inc., today announced that the companies have reached agreement        to amend the distribution rights to REMICADE<sup>\u00ae<\/sup> (infliximab)        and SIMPONI<sup>\u00ae<\/sup> (golimumab), which treat chronic inflammatory        diseases such as rheumatoid arthritis. This agreement concludes the        arbitration proceeding Johnson &amp; Johnson initiated in May 2009,        requesting a ruling related to the distribution agreement following the        announcement of the proposed merger between Merck and Schering-Plough.     <\/p>\n<p>       Under the terms of the amended distribution agreement, Merck&#8217;s        subsidiary, Schering-Plough (Ireland) will relinquish exclusive        marketing rights for REMICADE and SIMPONI to Johnson &amp; Johnson\u2019s Janssen        pharmaceutical companies in territories including Canada, Central and        South America, the Middle East, Africa and Asia Pacific* (\u201crelinquished        territories\u201d), effective July 1, 2011. Merck will retain exclusive        marketing rights throughout Europe, Russia and Turkey (\u201cretained        territories\u201d). The retained territories represent approximately 70        percent of Merck&#8217;s 2010 revenue of approximately $2.8 billion from        REMICADE and SIMPONI, while the relinquished territories represent        approximately 30 percent. In addition, all profit derived from Merck&#8217;s        exclusive distribution of the two products in the retained territories        will be equally divided between Merck and Johnson &amp; Johnson, beginning        July 1, 2011. Under the prior terms of the distribution agreement, the        contribution income (profit) split, which is currently at 58 percent to        Merck and 42 percent to Centocor Ortho Biotech Inc., would have declined        for Merck and increased for Johnson &amp; Johnson each year until 2014, when        it would have been equally divided. Johnson &amp; Johnson will also receive        a one-time payment of $500 million in April 2011. Merck expects to file        the amended agreement on a Form 8-K with the Securities and Exchange        Commission shortly.     <\/p>\n<p>       \u201cWe are pleased to have reached this voluntary agreement and look        forward to continuing to serve patients in need with REMICADE and        SIMPONI throughout Europe, Russia and Turkey,\u201d said Kenneth Frazier,        President and Chief Executive Officer of Merck. \u201cThe immunology field is        a rapidly growing therapeutic area. Merck will have a strong footprint        in this category through our significant retained interests in REMICADE        and SIMPONI, both of which will be important contributors to our overall        portfolio. We also are committed to ensuring a smooth transition for        customers and patients in the territories being relinquished, with no        impact on product supply.\u201d     <\/p>\n<p>       \u201cWe are pleased to have reached an amended agreement with Merck and        expand our market-leading immunology portfolio on a global basis,\u201d said        Bill Weldon, Chairman and Chief Executive Officer, Johnson &amp; Johnson.        \u201cThese important medicines provide very meaningful benefit to the        patients who depend upon them, and our first priority will be to ensure        the continued availability of REMICADE and SIMPONI to healthcare        providers and patients around the world, while continuing to increase        access. We are working closely with Merck to make certain this is a        seamless transition in the relinquished territories.\u201d     <\/p>\n<p>       [<b>EDITOR\u2019S NOTE:<\/b> In addition to this announcement, Merck and        Johnson &amp; Johnson issued separate news releases providing additional        financial information regarding this transaction to their respective        companies. A full listing of the territories is included below.]     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships that        donate and deliver our products to the people who need them. For more        information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=6685714&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=1ccc2c54c9a4168fb9b12594fff74b04\">www.merck.com<\/a>.     <\/p>\n<p>       <b>About Johnson &amp; Johnson<\/b>     <\/p>\n<p>       Caring for the world, one person at a time\u2026inspires and unites the        people of Johnson &amp; Johnson. We embrace research and science \u2014 bringing        innovative ideas, products and services to advance the health and        well-being of people. Our approximately 114,000 employees at more than        250 Johnson &amp; Johnson companies work with partners in health care to        touch the lives of over a billion people every day throughout the world.     <\/p>\n<p>       *In Japan, Indonesia, and Taiwan, Centocor Ortho Biotech Inc. will        continue to license distribution rights to REMICADE and SIMPONI to        Mitsubishi Tanabe Pharma Corporation.     <\/p>\n<p>       <b>Merck Forward Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=6685714&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=94c6e57eab9cba3bde6ff56a054cc994\">www.sec.gov<\/a>).     <\/p>\n<p>       <b>Johnson &amp; Johnson Forward Looking Statement<\/b>     <\/p>\n<p>       (This press release contains &#8220;forward-looking statements&#8221; as defined in        the Private Securities Litigation Reform Act of 1995. These statements        are based on current expectations of future events. If underlying        assumptions prove inaccurate or unknown risks or uncertainties        materialize, actual results could vary materially from the expectations        and projections of Centocor Ortho Biotech Inc. and\/or Johnson &amp; Johnson.        Risks and uncertainties include, but are not limited to, general        industry conditions and competition; economic factors, such as interest        rate and currency exchange rate fluctuations; technological advances and        patents attained by competitors; challenges inherent in new product        development, including obtaining regulatory approvals; domestic and        foreign health care reforms and governmental laws and regulations;        trends toward health care cost containment; and increased scrutiny of        the healthcare industry by government agencies. A further list and        description of these risks, uncertainties and other factors can be found        in Exhibit 99 of Johnson &amp; Johnson\u2019s Annual Report on Form 10-K for the        fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as        subsequent filings, are available online at <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6685714&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=788baf5e708e2658a9d84a17ec7f0192\">www.sec.gov<\/a>,        <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.jnj.com&amp;esheet=6685714&amp;lan=en-US&amp;anchor=www.jnj.com&amp;index=4&amp;md5=adb279a5c7011b4a348351c976711459\">www.jnj.com<\/a>        or on request from Johnson &amp; Johnson. Neither Centocor Ortho Biotech        Inc. nor Johnson &amp; Johnson undertake to update any forward-looking        statements as a result of new information or future events or        developments.)     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td colspan=\"4\">           &nbsp;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"4\">           <b>Territories Retained by Merck<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>Europe<\/b>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           &nbsp;         <\/td>\n<td>           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           France; Monaco; St. Pierre Et Miquelon;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Reunion; Germany; Italy; San Marino;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignl\">           Spain; Andorra; Ireland; United Kingdom (including         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Gibraltar and St. Helena); Portugal;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Azores; Madeira Islands; Holland; Belgium;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Luxembourg; Poland; Hungary; Czech Republic;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Slovak Republic; Greece; Cyprus; Malta; Romania;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Slovenia; Croatia; Bosnia\/Hercegovina; Bulgaria;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Serbia; Montenegro; Macedonia; Albania; Kosovo;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Switzerland; Liechtenstein; Austria; Denmark;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Greenland; Iceland; Norway; Finland; Latvia;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Estonia; Lithuania; Sweden;         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           &nbsp;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           <b>Emerging Markets<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Russia; Turkey           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           &nbsp;         <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td colspan=\"4\">           &nbsp;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"4\">           <b>Territories relinquished to Johnson &amp; Johnson as of July 1, 2011<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           <b>North America<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           Canada         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>Middle East, Africa, Belarus, Ukraine,<\/b>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           &nbsp;         <\/td>\n<td>           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Egypt; Saudi Arabia; United Arab Emirates; Kuwait; Bahrain;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>Central Asia and the Caucasus<\/b>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Qatar; Oman; Algeria; Morocco; Tunisia; Madagascar;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Mauritius; Comoro Islands; Djibouti; Burundi; Rwanda;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Mauritania; Cameroon; Central African Emp.; Chad;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Democratic Republic of the Congo; Benin; Gabon; Ivory         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Coast; Mali; Niger; Senegal; Guinea; Liberia; Sierra Leone;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Belarus; Moldova; Azerbaijan; Georgia; Armenia;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Kazakhstan; Kirgizia; Tadzhikistan; Turkmenia; Uzbekistan;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Iran; Yemen; Sudan; Libya; Lebanon; Syria; Jordan; Iraq;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Ukraine; Israel; Peoples Republic of Mongolia; South Africa;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Lesotho; Transkei; Swaziland; Angola; Mozambique;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Zimbabwe; Malawi; Guinea Bissau; Ethiopia; Sao Tome &amp;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Principe; Equatorial Guinea; Botswana; Eritrea; Kenya;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Tanzania; Uganda; Somalia; Nigeria; Seychelles; Pemba         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Island; Socotra; Namibia (South West Africa); Cape Verde;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Gambia; Ghana; Republic of Guinea; Togo; Burkina Faso;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           Congo         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>Latin America and Caribbean Islands<\/b>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Brazil; Argentina; Peru; Chile; Mexico; Costa Rica; El         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Salvador; Guatemala; Honduras; Nicaragua; Panama;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Dominican Republic; Belize; Venezuela; Colombia; Ecuador;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Bolivia; Guyana; Paraguay; Suriname; Uruguay; Antigua &amp;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Barbuda; Bahamas; Barbados; Cuba; Dominica; Grenada;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Haiti; Jamaica; Saint Kitts and Nevis; Saint Lucia;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           Saint Vincent and the Grenadines; Trinidad &amp; Tobago         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           <b>Asia Pacific<\/b>         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignl\">           Australia; New Zealand; India; Sri Lanka; Bangladesh; Korea;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Malaysia; Philippines; Singapore; Thailand; Pakistan;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Afghanistan; Bhutan; Brunei Drussalam; Cambodia; Fiji;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Kiribati; Lao People\u2019s DR; Maldives; Marshall Islands;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Micronesia; Myanmar; Nauru; Nepal; Palau; Papua New         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">           Guinea; Samoa; Solomon Islands; Timor Leste; Tonga;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           &nbsp;         <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">           Tuvalu         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           &nbsp;         <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>       Photos\/Multimedia&nbsp;Gallery Available: <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6685714%26lang%3Den&amp;esheet=6685714&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6685714%26lang%3Den&amp;index=5&amp;md5=f7af7d35db07558fd0251ed340ff9082\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=6685714&amp;lang=en<\/a>     <\/p>\n<p><p>       Media:<br \/>Merck:<br \/>David Caouette, 908-423-3461<br \/>Ron Rogers,        908-423-6449<br \/>or<br \/>Johnson &amp; Johnson:<br \/>Bill Price,        732-524-6623<br \/>Carol Goodrich, 732-524-6678<br \/>or<br \/>Investors:<br \/>Merck:<br \/>Joe        Romanelli, 908-423-5088<br \/>Carol Ferguson, 908-423-4465<br \/>or<br \/>Johnson        &amp; Johnson:<br \/>Stan Panasewicz, 732-524-2524<br \/>Louise Mehrotra,        732-524-6491<\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson &amp; Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc., today announced that the companies have reached agreement to amend the distribution rights to REMICADE \u00ae (infliximab) and SIMPONI \u00ae (golimumab), which treat chronic inflammatory diseases such as rheumatoid arthritis. This agreement concludes the arbitration proceeding Johnson &amp; Johnson initiated in May 2009, requesting a ruling related to the distribution agreement following the announcement of the proposed merger between Merck and Schering-Plough. Under the terms of the amended distribution agreement, Merck&#8217;s subsidiary, Schering-Plough (Ireland) will relinquish exclusive marketing rights for REMICADE and SIMPONI to Johnson &amp; Johnson\u2019s Janssen pharmaceutical companies in territories including Canada, Central and South America, the Middle East, Africa and Asia Pacific* (\u201crelinquished territories\u201d), effective July 1, 2011.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742129","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Johnson &amp; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Johnson &amp; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson &amp; Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc., today announced that the companies have reached agreement to amend the distribution rights to REMICADE \u00ae (infliximab) and SIMPONI \u00ae (golimumab), which treat chronic inflammatory diseases such as rheumatoid arthritis. This agreement concludes the arbitration proceeding Johnson &amp; Johnson initiated in May 2009, requesting a ruling related to the distribution agreement following the announcement of the proposed merger between Merck and Schering-Plough. Under the terms of the amended distribution agreement, Merck&#039;s subsidiary, Schering-Plough (Ireland) will relinquish exclusive marketing rights for REMICADE and SIMPONI to Johnson &amp; Johnson\u2019s Janssen pharmaceutical companies in territories including Canada, Central and South America, the Middle East, Africa and Asia Pacific* (\u201crelinquished territories\u201d), effective July 1, 2011.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\\\/\",\"name\":\"Merck and Johnson &amp; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-04-15T06:00:00+00:00\",\"dateModified\":\"2026-08-10T17:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Johnson &#038; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Johnson &amp; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Johnson &amp; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson &amp; Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc., today announced that the companies have reached agreement to amend the distribution rights to REMICADE \u00ae (infliximab) and SIMPONI \u00ae (golimumab), which treat chronic inflammatory diseases such as rheumatoid arthritis. This agreement concludes the arbitration proceeding Johnson &amp; Johnson initiated in May 2009, requesting a ruling related to the distribution agreement following the announcement of the proposed merger between Merck and Schering-Plough. Under the terms of the amended distribution agreement, Merck's subsidiary, Schering-Plough (Ireland) will relinquish exclusive marketing rights for REMICADE and SIMPONI to Johnson &amp; Johnson\u2019s Janssen pharmaceutical companies in territories including Canada, Central and South America, the Middle East, Africa and Asia Pacific* (\u201crelinquished territories\u201d), effective July 1, 2011.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:18+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/","name":"Merck and Johnson &amp; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-04-15T06:00:00+00:00","dateModified":"2026-08-10T17:01:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade-and-simponi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Johnson &#038; Johnson Reach Agreement on Distribution Rights for REMICADE\u00ae and SIMPONI\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0b4b83fd-ed24-4cea-8db7-8330cc6830bd","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Johnson--Johnson-Reach-Agreement-on-Distribution-Rights-for-REMICADE-and-SIMPONI-2011.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742129\/revisions"}],"predecessor-version":[{"id":3679265,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742129\/revisions\/3679265"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742129"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}